Association of serum levels of tissue inhibitors of metalloproteinase-1 with clinical outcome in children with biliary atresia

Asian Pacific Journal of Allergy and Immunology

Volumn 24, Issue 2-3, 2006, Pages 161-166

  Honsawek, Sittisak ^a   Chongsrisawat, Voranush ^a   Vejchapipat, Paisarn ^a   Thawornsuk, Nutchanart ^a   Poovorawan, Yong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT ATRESIA; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; JAUNDICE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOENTEROSTOMY;

BILIARY ATRESIA; CASE-CONTROL STUDIES; CHILD; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMANS; HYPERTENSION, PORTAL; INFLAMMATION; JAUNDICE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 33751017380     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Balistreri WF, Grand R, Hoofnagle JH, Suchy FJ, et al. Biliary atresia: current concepts and research directions. Summary of a symposium. Hepatology 1996; 23: 1682-92.
2. Karrer FM, Price MR, Bensard DD, et al. Long-term results with the Kasai operation for biliary atresia. Arch Surg 1996; 131: 493-6.
3. Chuang JH, Lin N. Biliary atresia at the dawn of a new century. Chang Gung Med J 2001; 24: 217-28.
4. Friedman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis 1990; 10: 20-9.
5. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-5.
6. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
7. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993; 59: 329-41.
8. Kobayashi H, Li ZX, Yamataka A, Lane GJ, Miyano T. Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in postoperative biliary atresia patients. J Pediatr Surg 2002; 37: 1030-3.
9. Urushihara N, Iwagaki H, Yagi T, et al. Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J Pediatr Surg 2000; 35: 446-9.
10. Chongsrisawat V, Chatchatee P, Samransamruajkit R, Vanapongtipagorn P, Chottivittayatarakorn P, Poovorawan Y. Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension. Pediatr Surg Int 2003; 19: 478-81.
11. Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, Tangkijvanich P, Poovorawan V. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. Pediatr Surg Int 2005; 21: 73-7.
12. Tamatani T, Kobayashi H, Tezuka K, et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998; 251: 748-52.
13. Chongsrisawat V, Ampai S, Chotivitayatarakorn P, Sirisopikul T, Poovorawan Y. Relationship between vasoactive intestinal peptide and intrapulmonary vascular dilatation in children with various liver diseases. Acta Paediatr 2003; 92: 1411-4.
14. Vejchapipat P, Theamboonlers A, Chaokhonchai R, Chongsrisawat V, Chittmittrapap S, Poovorawan V. Serum hepatocyte growth factor and clinical outcome in biliary atresia. J Pediatr Surg 2004; 39: 1045-9.
15. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993; 328: 1828-35.
16. Benyon RC, Arthur MJ. Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr 1998; 27: 75-85.
17. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
18. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-84.
19. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci 2006; 36: 23-30.
20. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-10.
21. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat. 2005; 89: 29-34.
22. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005; 11: 3257-64.
23. Pereira TN, Lewindon PJ, Smith JL, et al. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol 2004; 41: 576-83.
24. Walsh KM, Timms P, Campbell S, MacSween RNM, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624-30.
25. Li J, Rosman AS, Leo MA, Nagai Y. Lieber CS. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology 1994; 19: 1418-23.
26. Muzzillo DA, Imoto M, Fukuda Y, et al. Clinical evaluation of serum tissue inhibitor of metalloproteinase-1 levels in patients with liver diseases. J Gastroenterol Hepatol 1993; 8: 437-41.
27. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213-9.
28. Hsieh CS, Chuang JH, Huang CC, et al. Evaluation of matrix metalloproteinases and their endogenous tissue inhibitors in biliary atresia-associated liver fibrosis. J Pediatr Surg 2005; 40: 1568-73.
29. Choe BH, Kim KM, Kwon S, et al. The pattern of differentially expressed genes in biliary atresia. J Korean Med Sci 2003; 18: 392-6.